ArmaGen Technologies develops a platform to re-engineer recombinant proteins for blood–brain barrier penetration to treat diseases of the brain and spinal cord. The company is initially focusing on orphan CNS diseases with lead biopharmaceutical programs for Mucopolysaccharidosis (MPS) Type I (Hurler’s syndrome) and MPS Type II (Hunter’s disease). ArmaGen was formed in 2004 by William M. Pardridge, MD, who serves as Chief Scientific Officer, and is based in Santa Monica, CA. The company has raised $17M in Series A financing. The capital is intended to support expansion of existing operations and the clinical development of its biopharmaceuticals.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2012